This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shotland, L. I. Articles by Viner, J. L. Search for Related Content PubMed PubMed Citation Articles by Shotland, L. I. Articles by Viner, J. L.

Recommendations for Cancer Prevention Trials Using Potentially Ototoxic Test Agents

From the Hearing Section, Neuro-Otology Branch, and Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, and the Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Otolaryngology, University of Minnesota, Minneapolis, MN; and CCS Associates, Inc, Mountain View, CA.

Address reprint requests to Lawrence I. Shotland, PhD, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, 9000 Rockville Pike, Bldg 10, Rm 5C-306, Bethesda, MD 20892.

PURPOSE: Preventive oncology applies pharmacologic agents to reverse, retard, or halt progression of neoplastic cells to invasive malignancy, a process that may require administration of agents over long periods of time. Although ototoxicity may be a tolerable side effect of anticancer or antimicrobial therapy, even modest ototoxicity may not be acceptable in agents developed for preventive oncology that are routinely administered to subjects who neither are, nor necessarily will become, clinically ill.

MATERIALS AND METHODS: Age-related shifts in hearing may occur over the course of longterm or open-ended therapy; consequently, age-adjusted norms enable researchers to better distinguish hearing loss caused by drugs from that caused by aging. Norms for hearing sensitivity are derived from the Baltimore Longitudinal Study of Aging and are the basis for the proposed audiologic monitoring recommendations.

RESULTS: Audiologic monitoring recommendations are presented that standardize patient selection, adverse event reporting, posttreatment follow-up, and audiologic testing for potentially ototoxic investigational agents.

CONCLUSION: These recommendations are applicable to trials of investigational agents as well as various classes of drugs used in routine clinical care.

Portions of this work were presented at the Twelfth Annual Convention of the American Academy of Audiology, Chicago, IL, March 16-19, 2000.

This article has been cited by other articles:

				C. D. Lao, P. Backoff, L. I. Shotland, D. McCarty, T. Eaton, F. G. Ondrey, J. L. Viner, S. J. Spechler, E. T. Hawk, and D. E. Brenner Irreversible Ototoxicity Associated with Difluoromethylornithine Cancer Epidemiol. Biomarkers Prev., July 1, 2004; 13(7): 1250 - 1252. [Abstract] [Full Text] [PDF]

				C. J. Fabian, B. F. Kimler, D. A. Brady, M. S. Mayo, C. H. J. Chang, J. A. Ferraro, C. M. Zalles, A. L. Stanton, S. Masood, W. E. Grizzle, et al. A Phase II Breast Cancer Chemoprevention Trial of Oral {alpha}-Difluoromethylornithine: Breast Tissue, Imaging, and Serum and Urine Biomarkers Clin. Cancer Res., October 1, 2002; 8(10): 3105 - 3117. [Abstract] [Full Text] [PDF]